$TCRX

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

TScan Therapeutics (TCRX) announced a reorganization to focus on its in vivo solid tumor pipeline, reducing its workforce by 75%. The company paused enrollment in its Phase 3 ALLOHA-2 study due to funding constraints. TScan plans to release preclinical data in Q1 2027 and initiate Phase 1 development in Q4 2027. Shares were down 36.95% to 42 cents at the time of publication.

Wedbush downgraded Tscan Therapeutics (TCRX) to Neutral, lowering its price target to $1.00 from $5.00 due to a strategic shift. The company paused its Phase 3 ALLOHA-2 study and refocused on preclinical programs, reducing staff by 75%. Despite cash burn concerns, InvestingPro suggests the stock may be undervalued. H.C. Wainwright reiterated a Buy rating with a $7.00 target, citing positive trial data.

TScan Therapeutics (TCRX) reported that two in vivo TCR therapies for solid tumors have entered IND-enabling stages, with preclinical data and regulatory updates expected in Q1 2027 and a phase I trial planned for Q4 2027. The company's heme malignancy and autoimmune programs are paused pending partnerships. TCRX's financial runway extends to Q4 2027, according to a study update.

TScan Therapeutics (TCRX) shares fell 28.8% after announcing a strategic reorganization, including a 75% workforce reduction, pausing its Phase 3 ALLOHA-2 trial due to insufficient capital, and redirecting resources to solid tumor candidates. The company expects $55M in cost savings by 2027 and has a cash runway into Q4 2027. It is seeking collaboration partners for paused programs.

TScan Therapeutics (TCRX) is cutting 75% of its workforce and refocusing on solid tumor programs. The company expects $55M in savings through 2027 and plans to advance two product candidates. It paused enrollment in a Phase 3 trial due to insufficient capital and is seeking partners for its hematologic malignancies and autoimmune programs.

TScan Therapeutics, Inc. (TCRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated dat

Amgen (NASDAQ: AMGN) terminated its collaboration with TScan Therapeutics (NASDAQ: TCRX), ending over USD 500 million in potential milestone payments for TScan. The agreement, effective November 10, 2026, focused on TScan's T-cell receptor discovery platform for Crohn's disease. TScan reported progress in its Phase III ALLOHA-2 trial for TSC-101, a therapy for hematologic malignancies, with topline data expected mid-2028.

Amgen will terminate its research collaboration and license agreement with TScan Therapeutics, according to an SEC filing. The companies had been working together on developing novel cancer therapies.

TScan Therapeutics (TCRX) announced that Amgen has terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. TScan will not face penalties but will lose potential $500M+ in milestones and royalties. The company received a $30M upfront payment in 2023.